Category: Management

• Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake.
• Kim JO, Schaid DJ, Vachon CM, Cooke A, Couch FJ, Kim CA, Sinnwell JP, Hasadsri L, Stan DL, Goldenberg BA, Neal L, Grenier D, Degnim AC, Thicke LA, Pruthi S.
• Cancer Prev Res (Phila). 2020 Oct 23:canprevres.0154.2020. doi: 10.1158/1940-6207.CAPR-20-0154. Epub ahead of print.

• PMID: 33097489
• PubMed abstract
• Source abstract

• Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.
• Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.
• Cancer Treat Res Commun. 2020 Sep 28;25:100212. doi: 10.1016/j.ctarc.2020.100212. Epub ahead of print.

• PMID: 33091732
• PubMed abstract

• Free Full Text

• Cytologic studies of in vivo fallopian tube specimens in patients undergoing salpingo-oophorectomy.
• Pramanik S, Yang E, Wu W.
• Cytojournal. 2020 Aug 10;17:19. doi: 10.25259/CytoJournal_7_2020.

• PMID: 33093855
• PubMed abstract

• Free PMC article
• Free Full Text

• The factors associated with distress a minimum of six months after BRCA1/2 confirmation: A systematic review.
• Butler E, Collier S, Hevey D.
• J Psychosoc Oncol. 2020 Oct 22:1-27. doi: 10.1080/07347332.2020.1836109. Epub ahead of print.

• PMID: 33089755
• PubMed abstract
• Source abstract

• Review

• Lessons learned from setting up a prospective, longitudinal, multicenter study with women at high risk for breast cancer.
• Patuleia SIS, Hagenaars SC, Moelans CB, Ausems MGEM, van Gils CH, Tollenaar RAEM, Van Diest PJ, Mesker WE, van der Wall E.
• Cancer Epidemiol Biomarkers Prev. 2020 Oct 20:cebp.0770.2020. doi: 10.1158/1055-9965.EPI-20-0770. Epub ahead of print.

• PMID: 33082203
• PubMed abstract

• Review

• Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
• Kim SR, Tone A, Kim R, Cesari M, Clarke B, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE.
• Int J Gynecol Cancer. 2020 Oct 20:ijgc-2020-001927. doi: 10.1136/ijgc-2020-001927. Epub ahead of print.

• PMID: 33082239
• PubMed abstract
• Source abstract

• ASO Author Reflections: Contralateral Prophylactic Mastectomy in Breast Cancer Patients with CHEK2 Gene Mutations.
• Nizic-Kos T, Besic N.
• Ann Surg Oncol. 2020 Oct 18. doi: 10.1245/s10434-020-09196-w. Epub ahead of print.

• PMID: 33073339
• PubMed abstract
• Source abstract

• Commentary

• Repurposing denosumab in breast cancer beyond prevention of skeletal related events: could nonclinical data be translated into clinical practice?
• Deligiorgi MV, Panayiotidis MI, Trafalis DT.
• Expert Rev Clin Pharmacol. 2020 Oct 17. doi: 10.1080/17512433.2020.1839416. Epub ahead of print.

• PMID: 33070648
• PubMed abstract
• Source abstract

• Review

• Comparison of interval breast cancers with 2D digital mammography versus 3D digital breast tomosynthesis in a large community-based practice.
• Winter AM, Kazmi S, Hardy AK, Bennett DL.
• Breast J. 2020 Oct 16. doi: 10.1111/tbj.14047. Epub ahead of print.

• PMID: 33064341
• PubMed abstract
• Source abstract

• Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study.
• Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, Wright F, Lerner-Ellis J, McCuaig J, Graham T, Sun P, Akbari M, Narod SA.
• Ann Surg Oncol. 2020 Sep 28. doi: 10.1245/s10434-020-09160-8. Epub ahead of print.

• PMID: 32989658
• PubMed abstract
• Source abstract

• Significance of E-cadherin Gene Mutations in Patients With Hereditary Diffuse Gastric Cancer Syndrome: A Systematic Review.
• Goud HK, Mehkari Z, Mohammed L, Javed M, Althwanay A, Ahsan F, Oliveri F, Rutkofsky IH.
• Cureus. 2020 Sep 12;12(9):e10406. doi: 10.7759/cureus.10406.

• PMID: 33062523
• PubMed abstract

• Review
• Free PMC article
• Free Full Text

• Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review.
• Yadav G, Vashisht M, Yadav V, Shyam R.
• Int J Prev Med. 2020 Sep 3;11:135. doi: 10.4103/ijpvm.IJPVM_75_19.

• PMID: 33088463
• PubMed abstract
• Source abstract

• Review
• Free PMC article
• Free Full Text

• Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes.
• Singer CF.
• Horm Mol Biol Clin Investig. 2020 May 7;41(3):/j/hmbci.2020.41.issue-3/hmbci-2019-0057/hmbci-2019-0057.xml. doi: 10.1515/hmbci-2019-0057.

• PMID: 32989958
• PubMed abstract
• Source abstract

• Review

• Testing a Best Practices Risk Result Format to Communicate Genetic Risks.
• Davis K, Roter DL, Schmidlen T, Scheinfeldt LB, Klein WMP.
• Patient Educ Couns. 2020 Oct 19:S0738-3991(20)305589. doi: 10.1016/j.pec.2020.10.021. Epub ahead of print.

• Source abstract

• How Patients Deal with an Ambiguous Medical Test: Decision-Making after Genetic Testing.
• Scherra CL, Ramesh S, Getachew-Smith H, Kalke K, Ramsey K, Fischhoff B, Vadaparampil ST.
• Patient Educ Couns. 2020 Oct 18:S0738-3991(20)305577. doi: 10.1016/j.pec.2020.10.020. Epub ahead of print.

• Source abstract

• Development and Implementation of an Algorithm to Guide MRI Screening in Patients with a Personal History of Treated Breast Cancer.
• Strigel RM, Bravo E, Tevaarwerk AJ, Anderson BM, Stella AL, Neuman HB.
• Clin Breast Cancer. 2020 Oct 17:S1526-8209(20)30021-5. doi: 10.1016/j.clbc.2020.01.005. Epub ahead of print.

• Source abstract

• Two-Stage Surgery to Reduce Ovarian Cancer Risk Piques Interest.
• Worcester S.
• Medscape. News & Perspective. 2020 Oct 16.

• Research news
• Free Full Text

Related:

Original research:

Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.

• PMID: 32803845
• PubMed abstract
• Free Full Text

• Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.
• Kobayashi Y, Hirasawa A, Chiyoda T, Ueki A, Masuda K, Misu K, Kawaida M, Hayashi S, Kataoka F, Banno K, Kosaki K, Aoki D.
• Jpn J Clin Oncol. 2020 Oct 10:hyaa173. doi: 10.1093/jjco/hyaa173. Epub ahead of print.

• PMID: 33037428
• PubMed abstract
• Source abstract

• Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?
• Fadda M, Chappuis PO, Katapodi MC, Pagani O, Monnerat C, Membrez V, Unger S, Caiata Zufferey M.
• PLoS One. 2020 Oct 8;15(10):e0240054. doi: 10.1371/journal.pone.0240054.

• PMID: 33031463
• PubMed abstract

• Free Full Text

• Advances in epithelial ovarian cancer.
• Neesham D, Richards A, McGauran M.
• Aust J Gen Pract. 2020 Oct;49(10):665-669.

• PMID: 33015682
• PubMed abstract

• Review
• Free Full Text

• Young women's decision-making and experience of using tamoxifen to reduce BRCA1/2 breast cancer risk: a qualitative study.
• Forrest LE, Shepherd RF, Young MA, Keogh LA, James PA.
• Psychooncology. 2020 Oct 1. doi: 10.1002/pon.5556. Epub ahead of print.

• PMID: 33006205
• PubMed abstract
• Source abstract

• Breast cancer screening in women at high risk of hereditary breast cancer: an Australian experience.
• Bennett I, Tourani S, Cockburn L, Reasbeck J, Grobbelaar N, Dann S, Patrikios P, Brazier J.
• ANZ J Surg. 2020 Sep 30. doi: 10.1111/ans.16320. Epub ahead of print.

• PMID: 33000553
• PubMed abstract
• Source abstract